Evidence map›Paper›PMID 31052520›Full record

ArticleInternational journal of molecular sciences2019

How to Steer and Control ERK and the ERK Signaling Cascade Exemplified by Looking at Cardiac Insufficiency.

Tim Breitenbach, Kristina Lorenz, Thomas Dandekar

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. ERK1/2 Activity Is Critical for the Outcome of Ischemic Stroke.International journal of molecular sciences · 2022
    Article
  7. Article
  8. Alveolar Regeneration in COVID-19 Patients: A Network Perspective.International journal of molecular sciences · 2021
    Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Tim BreitenbachBiozentrum, Universität Würzburg, Am Hubland, 97074 Würzburg, Germany. tim.breitenbach@freenet.de.
Kristina LorenzInstitute of Pharmacology and Toxicology, Versbacher Straße 9, 97078 Würzburg, Germany. lorenz@toxi.uni-wuerzburg.de.
Thomas DandekarBiozentrum, Universität Würzburg, Am Hubland, 97074 Würzburg, Germany. dandekar@biozentrum.uni-wuerzburg.de.ORCID 0000-0003-1886-7625
University of Würzburg · DE

Funding

Deutsche Forschungsgemeinschaft 374031971 - TRR 240/Z2
6 · The paper itself

Abstract

Mathematical optimization framework allows the identification of certain nodes within a signaling network. In this work, we analyzed the complex extracellular-signal-regulated kinase 1 and 2 (ERK1/2) cascade in cardiomyocytes using the framework to find efficient adjustment screws for this cascade that is important for cardiomyocyte survival and maladaptive heart muscle growth. We modeled optimal pharmacological intervention points that are beneficial for the heart, but avoid the occurrence of a maladaptive ERK1/2 modification, the autophosphorylation of ERK at threonine 188 (ERK Thr 188 phosphorylation), which causes cardiac hypertrophy. For this purpose, a network of a cardiomyocyte that was fitted to experimental data was equipped with external stimuli that model the pharmacological intervention points. Specifically, two situations were considered. In the first one, the cardiomyocyte was driven to a desired expression level with different treatment strategies. These strategies were quantified with respect to beneficial effects and maleficent side effects and then which one is the best treatment strategy was evaluated. In the second situation, it was shown how to model constitutively activated pathways and how to identify drug targets to obtain a desired activity level that is associated with a healthy state and in contrast to the maleficent expression pattern caused by the constitutively activated pathway. An implementation of the algorithms used for the calculations is also presented in this paper, which simplifies the application of the presented framework for drug targeting, optimal drug combinations and the systematic and automatic search for pharmacological intervention points. The codes were designed such that they can be combined with any mathematical model given by ordinary differential equations.

Indexed as

AlgorithmsCardiomegalyHumansMAP Kinase Signaling SystemMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Models, CardiovascularMolecular Targeted TherapyMyocytes, CardiacPhosphorylationMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3efficient intervention pointsERK signalingoptimal drug combinationoptimal drug targetingoptimal pharmacological modulationoptimal treatment strategies

Identifiers

PMID31052520
PMCPMC6539830
OpenAlexW2943549269

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.